Sarepta Therapeutics is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing and commercializing of some of their medical products and therapeutics.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“There is no guarantee that the FDA will agree to this approach to the development of our infectious disease product candidate, considering that no validated animal model has been established as predicting human outcomes in the prevention or treatment of any filovirus disease. Animal models represent, at best, a rough approximation of efficacy in humans, and, as such, countermeasures developed using animal models will be untested until their use in humans during an emergency.” Read the full document
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). The Company is primarily focused on the development of its disease-modifying DMD drug candidates. [Source: Reuters]
Company Website: https://www.sarepta.com